Table 6 Net clinical benefit of all patients with atrial fibrillation taking oral anticoagulants based on CHA₂DS₂-VASc score

Any OACs vs. No OACs

 CHA₂DS₂-VASc of 0–1

0.04 (0.04 to 0.05)

-0.37 (-0.79 to 0.05)

-0.78 (-1.62 to 0.05)

 CHA₂DS₂-VASc of 2

-1.78 (-2.07 to -1.49)

-2.41 (-3.34 to -1.48)

-3.04 (-4.61 to -1.46)

 CHA₂DS₂-VASc of ≥ 3

0.52 (0.33 to 0.73)

0.04 (-0.31 to 0.39)

-0.44 (-1.34 to 0.46)

Warfarin vs. No OACs

 CHA₂DS₂-VASc of 0–1

-0.17 (-0.28 to -0.05)

-0.67 (-1.27 to -0.07)

-1.18 (-2.26 to -0.09)

 CHA₂DS₂-VASc of 2

-1.97 (-2.29 to -1.65)

-2.69 (-3.68 to -1.70)

-3.41 (-5.07 to -1.75)

 CHA₂DS₂-VASc of ≥ 3

0.38 (0.19 to 0.58)

-0.13 (-0.49 to 0.23)

-0.65 (-1.57 to 0.27)

DOACs vs. No OACs

 CHA₂DS₂-VASc of 0–1

1.18 (0.70 to 1.66)

1.25 (0.92 to 1.59)

1.33 (1.14 to 1.52)

 CHA₂DS₂-VASc of 2

0.31 (-1.03 to 1.64)

0.73 (-0.13 to 1.59)

1.15 (0.77 to 1.54)

 CHA₂DS₂-VASc of ≥ 3

2.19 (1.82 to 2.57)

2.08 (0.73 to 3.42)

1.96 (-0.36 to 4.27)

Warfarin (TTR ≥ 65%) vs. No OACs

 CHA₂DS₂-VASc of 0–1

-0.33 (-1.31 to 0.64)

-1.02 (-2.86 to 0.82)

-1.70 (-4.41 to 1.01)

 CHA₂DS₂-VASc of 2

-0.63 (-1.12 to -0.13)

-0.97 (-2.24 to 0.31)

-1.31 (-3.36 to 0.75)

 CHA₂DS₂-VASc of ≥ 3

2.63 (2.52 to 2.73)

2.72 (2.22 to 3.23)

2.82 (1.72 to 3.93)

DOACs versus Warfarin

 CHA₂DS₂-VASc of 0–1

1.35 (0.80 to 1.90)

1.93 (0.92 to 2.93)

2.50 (1.03 to 3.97)

 CHA₂DS₂-VASc of 2

2.28 (0.96 to 3.60)

3.42 (2.57 to 4.28)

4.56 (4.18 to 4.95)

 CHA₂DS₂-VASc of ≥ 3

1.81 (1.10 to 2.53)

2.21 (0.60 to 3.82)

2.60 (0.10 to 5.11)

DOACs versus Warfarin (TTR ≥ 65%)

 CHA₂DS₂-VASc of 0–1

1.51 (-0.20 to 3.23)

2.27 (-0.30 to 4.84)

3.03 (-0.40 to 6.46)

 CHA₂DS₂-VASc of 2

0.93 (-0.12 to 1.98)

1.69 (1.25 to 2.14)

2.46 (2.29 to 2.63)

 CHA₂DS₂-VASc of ≥ 3

-0.43 (-1.19 to 0.33)

-0.65 (-2.34 to 1.04)

-0.87 (-3.48 to 1.75)